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Abtract
Objective: the retinoblastoma protein-interacting zinc
finger gene RIZ1 is a tumor suppressor gene and a
member  of  a  nuclear  histone/protein  methyltrans-
ferase superfamily. the purpose of the present study
was to examine the expression of RIZ1 and evaluate
its carcinogenesis in cervical cancer. the relationship
between DNA methylation and transcriptional silenc-
ing of RIZ1 was investigated in cervical cancer.
Methods:  RIZ1  expression  was  examined  in  cervical
cancer cell lines and cervical tissues (12 normal and 40
cancerous)  by  using  Rt  polymerase  chain  reaction
(PCR). Methylation status of the RIZ1 promoter was
studied using methylation-specific PCR (MSP).
Results: RIZ1 expression is reduced or lost in cervical
cancers,  compared  with  normal  cervical  tissues  (P
<0.05).  the  current  study  results  also  showed  that
loss of RIZ1 is mediated by aberrant cytosine methy-
lation  of  the  RIZ1  promoter.  37.5%  of  carcinomas
were methylated, while none of normal tissues were
methylated. RIZ1 mRNA expression was significantly
higher (P = 0.000) in unmethylated (0.3494 ﾱ 0.0466,
mean  ﾱSD),  compared  with  methylated  tissues
(0.1422  ﾱ  0.1073,  mean  ﾱSD).  treatment  with  a
DNA methyltransferase inhibitor led to reactivation of
RIZ1 expression in cell lines that had negligible RIZ1
expression at baseline. 
Conclusions: Reduced expression of RIZ1 may play an
important  role  in  the  pathogenesis  and/or  develop-
ment  of  cervical  cancer,  and  is  considered  to  be
caused in part by aberrant DNA methylation.
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INtRoDuCtIoN
Epigenetic phenomena such as DNA methylation and
alterations in the chromatin structure are increasingly
recognized as important mechanisms that are respon-
sible for tumor-suppressor inactivation. Recent studies
have shown that promoter hypermethylation is an im-
portant  mechanism  in  transcriptional  silencing  of
genes during cervical carcinogenesis. Investigations by
various  authors  have  demonstrated  that  expression
levels  of  p16,  RASSf1A,  DNMt3l,  fHIt,  CoX-2
and DAPK are altered by promoter hypermethylation
in cervical cancers [1–5].
the retinoblastoma protein-interacting zinc finger
gene (RIZ or PRDM2) was initially isolated in a func-
tional screening for Rb-binding proteins [6]. RIZ is a
member of the nuclear protein methyltransferase su-
perfamily. the gene maps to chromosome 1p36, a re-
gion commonly deleted in more than a dozen different
types  of  human  cancers  [7].  RIZ1  produces  two
mRNA and protein products. RIZ1 contains a novel
protein methyltransferase domain, whereas RIZ2 lacks
this domain [8]. RIZ1, but not RIZ2, has been shown
to  have  tumor  suppressor  activity.  RIZ1  knockout
mice  have  increased  tumor  susceptibility  [9].  Aden-
ovirus-mediated  RIZ1  expression  causes  G2-M  cell
cycle  arrest  and/or  apoptosis  in  breast  cancer,  liver
cancer,  and  microsatellite  instability-positive  colon
cancer cells [10–12]. RIZ1 expression, but not RIZ2
expression,  is  commonly  silenced  in  many  types  of
human tumors, including breast cancer, thyroid cancer,
liver  cancer,  colon  cancer,  neuroblastoma,melanoma,
lung cancer, and osteosarcoma [10–13].
DNA methylation has an essential regulatory func-
tion in mammalian development, suppressing gene ac-
tivity by changing chromatin structure [14, 15]. It has
become apparent that aberrant DNA methylation of
promoter region CpG islands may serve as an alter-
nate mechanism to genetic defects in the inactivation
of  tumor  suppressor  genes  in  human  malignancies
[16, 17]. Promoter hypermethylation has been shown
to be associated with reduced RIZ1 expression in solid
tumors, such as gastric and gallbladder carcinomas,in
addition to leukemias [18–21]. treatment with a DNA
methyltransferase  inhibitor,  5-aza-2ﾴdeoxycytidine  (5-
aza-dC) has been shown to activate RIZ1 mRNA ex-
pression  in  carcinoma  cell  lines  that  have  reduced
RIZ1 expression at baseline [18, 22, 23]. RIZ1 mis-
sense inactivating mutations have also been described
[24–26]. Interestingly, all of these have been shown to
be restricted to the protein methyltransferase domain,
which  expresses  protein  methyltransferase  activity
[22].
the expression and role of RIZ1 have not been ex-
amined  in  cervical  cancers.  our  results  show  that
RIZ1 mRNA expression is reduced or lost in cervical
cancer and associated with promoter methylation. 
MAtERIAlS AND MEtHoDS
CEll lINES AND tISSuES
We  obtained  four  cervical  cancer  cell  lines  (Hela,
SiHa, CaSki and C33) from the American type Cul-
ture  Collection  (Manassas,  vA,  uSA).  All  cell  lines
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3. Cheng_Umbruchvorlage  20.01.10  12:42  Seite 20were  grown  in  DMEM  (Invitrogen,  Carlsbad,  CA)
plus 10% fCS (Invitrogen, Carlsbad, CA) at 37ﾰC and
5% Co2. 12 normal cervix and 40 cervical cancer tis-
sues(two adenocarcinoma and 38 squamous cell carci-
noma)  were  obtained  from  the  tumor  Hospital  of
Harbin Medical university. the tissues were harvested
and  frozen  in  liquid  nitrogen  at  the  time  of  opera-
tion.the samples were stored at -70ﾰC until further
use.Informed consent was abtained from all study par-
ticipants.
DRuG tREAtMENt
Cancer cells (5 x 106 cells) were grown for 4 days in
the presence of various concentrations of 5-aza-2`-de-
oxycytidine (5-aza-dC; Sigma, St. louis, Mo, uSA), a
known DNA methyltransferase inhibitor. total RNA
was  isolated  and  used  for  Rt–PCR  analysis  as  de-
scribed  below.  Genomic  DNAs  were  isolated  from
treated and nontreated cells and used for MSP assays
as described below.
REvERSE tRANSCRIPtIoN AND SEMI-QuANtItAtIvE
Rt- PCR
total RNA was isolated from cervical tissues and cell
lines using tRIzol (Invitrogen, Carlsbad, CA). Reverse
transcription  was  performed  using  M-Mlv  reverse
transcriptase  and  random  oligonucleotide.  the  first-
strand  cDNA  sample  was  then  amplified  using  5ﾴ-
CAtACAACtGAAGACAAGtGAG-3ﾴ  and  5ﾴ-tAA
tCGCtCGtCtGGttC-3ﾴ (208 bp). the primers for
amplification  of  human  b-actin  are  5ﾴ-GtG  GGG
CGC  CCC  AGG  CAC  CA-3ﾴand  5ﾴ-CtCCttAAt
GtCACGCACGAtttC-3ﾴ. PCR reactions were run
for 30 cycles. the PCR products were analysed by gel
electrophoresis  followed  by  ethidium  bromide  stain-
ing.
DNA EXtRACtIoN AND MEtHylAtIoN ANAlySIS
Genomic  DNAs  from  tumor  tissues  and  cell  lines
were extracted using universal Genomic DNA Extrac-
tion Kit ver 3.0 (takara, tokyo, Japan). the quality
and  integrity  of  the  DNAwas  determined  by  the
A260/280 ratios. Genomic DNA (1ﾵg) was modified
with sodium bisulfite using EZ-DNA methylation kit
(Zymo research, orange, CA). Bisulfite-treated DNA
was used for methylation-specific PCR by using previ-
ously published primer sets [22] to distinguish between
methylated and unmethylated DNA. the PCR prod-
ucts were electrophoresed on a 2% agarose gel.
StAtIStICAl ANAlySIS
Gene expression levels are reported as mean ﾱ stan-
dard  deviation  (SD).  RIZ1  mRNA  expression  levels
were  normal  distribution  and  equal  variances,which
were compared by using t test. the correlation be-
tween methylation frequencies and clinicopathological
characteristics  was  compared  with  the  fisher  exact
test. All statistical tests were 2-sided and performed at
the 5% level of significance using the SPSS10.0 soft-
ware package.
RESultS
RIZ1 MRNA EXPRESSIoN IN CERvICAl CANCER CEll
lINES AND PRIMARy tuMoRS
to study the expression of RIZ1 gene in cervical can-
cer, we performed Rt–PCR analysis. RIZ1 expression
was reduced or lost in three of four cervical cancer
cell lines (fig. 1a). RIZ1 mRNA expression levels in
normal and primary tumor tissues are shown in figure
1b and table 1. RIZ1 mRNA expression in cervical
cancer tissues was significantly lower than that in nor-
mal tissues (P = 0.000)
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Table1. RIZ1 mRNA expression levels in normal cervical tis-
sues and tumors.
n mean SD SE tP
Normal  12 0.5227 0.094 0.0271
6.388 0
Malignant 40 0.2717 0.1256 0.0199
SD indicates standard deviation; SE, standard error; p<0.05
Fig. 1. (a) RIZ1 mRNA in cervical cancer cell lines relative to
normal tissues (n=12) .RIZ1 mRNA expression was absent in
2 of 4 cervical cancer cell lines . (b) RIZ1 mRNA expression in
normal tissues(N) and match tumor tissues(t). RIZ1 mRNA
expression  in  cervical  cancer  tissues  was  significantly  lower
than that in normal tissues(P<0.05). (c) Reactivation of RIZ1
expression by inhibitor of DNA methylation in SiHa cells.
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3. Cheng_Umbruchvorlage  20.01.10  12:42  Seite 21to  determine  whether  DNA  methylation  plays  a
role in silencing RIZ1 gene expression, we investigated
whether RIZ1 expression can be activated by 5-aza-
dC, an inhibitor of DNA methylation. SiHa cells were
treated with 1 uM of 5-aza-dC for 4 days. By Rt–PCR
analysis, 5-aza-dC treatment reactivated RIZ1 expres-
sion (fig. 1c). this result suggests a probable role of
DNA methylation in silencing RIZ1 gene expression.
RIZ1 PRoMotER MEtHylAtIoN StAtuS IN CERvICAl
CANCER CEll lINES AND PRIMARy tuMoRS
As shown in figure 2a, methylation of RIZ1 promoter
CpG island was found in Hela and SiHa cancer cells.
In  contrast,  the  promoter  was  unmethylated  in  C33
cell  line,  which  had  retained  RIZ1  expression.  Both
methylated and unmethylated products were observed
in the CaSki cell line, which displayed decreased (but
detectable) amounts of RIZ1 expression.
RIZ1 promoter methylation frequency was also ex-
amined in normal and primary cervical cancer tissues
by methylation specific PCR.15 of 40 (37.5 %) carci-
nomas showed evidence of RIZ1 promoter methyla-
tion, ie, a band was detected by using primers specific
for the methylated product. only unmethylated band
was detected in all normal cervical tissues (fig. 2a). to
determine whether transcriptional silencing of RIZ1 is
significantly associated with promoter hypermethyla-
tion in cervical cancer tissues, we assessed the correla-
tion between methylation status and RIZ1 mRNA ex-
pression.  RIZ1  mRNA  expression  was  significantly
higher (P = 0.000) in unmethylated (0.3494 ﾱ 0.0466,
meanﾱSD), compared with methylated tissues (0.1422
ﾱ 0.1073, mean ﾱSD), as shown in figure 2b. No sig-
niﬁcant correlation was detected between methy  lation
status and clinicopathological characteristics,as shown
in table 2.
We also used MSP assay to test whether demethyla-
tion might be induced by 5-aza-dC treatment, which
may correlate with reactivation of RIZ1 expression in
SiHa cell. As shown in figure 2c, 5-aza-dC treatment
led to an increase in the proportion of unmethylated
DNA versus methylated DNA.
DISCuSSIoN
Silencing of tumor suppressor genes is important in
initiation and progression of cancers. RIZ1 has been
reported to possess tumor suppressor activity, and its
expression is lost in many carcinoma cell lines and pri-
mary tumors. the expression and role of RIZ1 have
not been examined in cervical cancers. We hypothe-
sized that loss of RIZ1 expression is important in cer-
vical tumorigenesis and that this is mediated by hyper-
methylation (which can be inhibited by 5-aza-dC). Be-
cause promoter hypermethylation is strongly associat-
ed with loss of mRNA expression,we then examine
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Table 2. Correlation between RIZ1 methylation and clinico-
pathological parameters in cervical cancer.
Methylation*
factor
% (Me/total) P-value
tumor size(cm)
<4 34.6 (9/26)
0.736
≥4 42.9 (6/14)
tumor grade
G1+G2 34.8 (8/23)
0.749
G3 41.2 (7/17)
tumor stage
I 46.7 (7/15)
0.502
II+III 32.0 (8/25)
pelvic lymph nodes
Negative 33.3 (10/30)
0.457
Positive 50.0 (5/10)
*Samples that showed partials methylation are included
Fig. 2. a) Methylation-specific PCR analysis of various cervical cancer cell lines and all of primary tumors and normal tissues.
Bisulfite-treated DNA was used as a template for methylation-specific PCR by using previously described primers. M = primers
specific to methylated template DNA, u = primers specific to unmethylated template DNA, t = tumor, N = normal b) RIZ1
mRNA expression in methylated and unmethylated cervical cancer tissues. c) Methylation status of SiHa cell line before and 
after treatment with the DNA methyltransferase-inhibiting agent, 5-aza-dC.
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cancer cells and tissues. In our study, the RIZ1mRNA
expression in cervical cancer tissues was significantly
lower than that in normal cervical tissues (P <0.05).
RIZ1 expression was reduced or lost in three of four
cervical  cancer  cell  lines.  these  results  suggest  that
RIZ1 may function as a potential tumor suppressor
gene in cervical cancer, as in other malignant tumors. 
the RIZ1 promoter has been demonstrated to have
the  characteristics  of  a  CpG  island,  which  suggests
that  RIZ1  is  a  target  of  inactivation  by  epigenetic
mechanisms  [22].  DNA  methylation  was  a  common
mechanism  of  gene  silencing.  In  prostate  cancer,
42.6% of cancer cases were reported to have methyla-
tion of RIZ1 [27]. In gastric adenocarcinoma, hyper-
methylation of RIZ1 was found in 69% of cancer tis-
sues and in 21% of corresponding non-neoplastic mu-
cosa [18]. In thyroid carcinoma, all of the 19 cancer
cases were methylated, and was significantly frequent
compared with normal thyroid tissues (33%) [13]. Du
et al. reported that methylation of RIZ1 was detected
in 44% of breast cancer specimens and 62% of liver
cancer specimens [22]. In the present study the RIZ1
mRNA expression was low or undetected in cervical
cancer  tissues  and  cell  lines.  the  SiHa  cell  line  was
treated with 5-aza-dC (methyltransferase inhibitor), in
order to determined whether DNA methylation was
the cause of transcriptional silencing of RIZ1.In the
SiHa cell line the mRNA expression of RIZ1 was re-
covered after treatment with 5-aza-dC, indicating that
aberrant DNA methylation is likely to cause transcrip-
tional silencing. our data show that the incidence of
RIZ1  gene  promoter  methylation  was  relatively  less
frequent  compared  with  previous  studies  noted.
Methylation was found in 37.5 % (15/40) of cervical
cancer  tissues  and  none  of  normal  cervical  tissues.
the  difference  reached  statistical  significance  (P
<0.05). furthermore,in the cervical cancer tissues the
RIZ1 mRNA expression was obviously higher in the
unmethylated than that in the methylated (P <0.05),
which suggests that methylation of the RIZ1 promot-
er may contribute to cervical carcinogenesis. We found
no  correlation  between  methylation  and  any  of  the
clinicopathological characteristics of the patients.
In the present study the unmethylated form of the
RIZ1  promoter  was  detected  in  tumor  and  normal
samples. It is not surprising because the samples were
not separated using laser-capture microdissection, and
thus they can be expected to contain both normal and
tumor  tissues.  Several  cases  demonstrated  relatively
low levels of RIZ1 expression in the absence of RIZ1
promoter methylation. We speculate that there may be
other mechanisms that are involved in RIZ1 gene si-
lencing. Such mechanisms may include histone methy-
lation,  mutations  in  promoter  sequences  and  DNA
methylation in other promoter regions not covered by
our present PCR primer set.
the present results suggest that RIZ1 is a potential
tumor suppressor gene and transcriptional silencing of
this gene is caused in part by DNA promoter methyla-
tion in cervical cancer. It is also suggested that epige-
netic silencing of RIZ1 (e.g., methylation of its 5-CpG
island) plays an important role in the progression of
cervical cancer, and may be a useful molecular target
for  diagnosis  and  therapy.  Infection  with  oncogenic
HPv is the most significant risk factor in cervical can-
cer. transcriptional inactivation of the RIZ1 gene may
be  induced  by  oncogenic  HPv.  the  association  be-
tween the RIZ1 methylation and HPv genotypes will
be investigated in the future.
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